BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

857 related articles for article (PubMed ID: 26970772)

  • 1. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis.
    Haukaas FS; Arnesen TM; Winje BA; Aas E
    Eur J Health Econ; 2017 May; 18(4):405-415. PubMed ID: 26970772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review.
    Greenaway C; Pareek M; Abou Chakra CN; Walji M; Makarenko I; Alabdulkarim B; Hogan C; McConnell T; Scarfo B; Christensen R; Tran A; Rowbotham N; van der Werf MJ; Noori T; Pottie K; Matteelli A; Zenner D; Morton RL
    Euro Surveill; 2018 Apr; 23(14):. PubMed ID: 29637889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the cost-effectiveness of two screening strategies for latent tuberculosis infection in Portugal.
    Sousa S; Rocha D; Silva JC; Ribeiro AI; Gonçalves G; Almeida Á; Correia AM; Duarte R; Carvalho C
    Pulmonology; 2021; 27(6):493-499. PubMed ID: 34053903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model.
    Tasillo A; Salomon JA; Trikalinos TA; Horsburgh CR; Marks SM; Linas BP
    JAMA Intern Med; 2017 Dec; 177(12):1755-1764. PubMed ID: 29049814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries.
    Hardy AB; Varma R; Collyns T; Moffitt SJ; Mullarkey C; Watson JP
    Thorax; 2010 Feb; 65(2):178-80. PubMed ID: 19996345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Added value of interferon-gamma release assays in screening for tuberculous infection in the Netherlands.
    Erkens CG; Dinmohamed AG; Kamphorst M; Toumanian S; van Nispen-Dobrescu R; Alink M; Oudshoorn N; Mensen M; van den Hof S; Borgdorff M; Verver S
    Int J Tuberc Lung Dis; 2014 Apr; 18(4):413-20. PubMed ID: 24670695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review on TST and IGRA tests used for diagnosis of LTBI in immigrants.
    Campbell JR; Krot J; Elwood K; Cook V; Marra F
    Mol Diagn Ther; 2015 Feb; 19(1):9-24. PubMed ID: 25579159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberculosis progression rates in U.S. Immigrants following screening with interferon-gamma release assays.
    Blount RJ; Tran MC; Everett CK; Cattamanchi A; Metcalfe JZ; Connor D; Miller CR; Grinsdale J; Higashi J; Nahid P
    BMC Public Health; 2016 Aug; 16(1):875. PubMed ID: 27558397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community-based evaluation of immigrant tuberculosis screening using interferon γ release assays and tuberculin skin testing: observational study and economic analysis.
    Pareek M; Bond M; Shorey J; Seneviratne S; Guy M; White P; Lalvani A; Kon OM
    Thorax; 2013 Mar; 68(3):230-9. PubMed ID: 22693179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis.
    Pooran A; Booth H; Miller RF; Scott G; Badri M; Huggett JF; Rook G; Zumla A; Dheda K
    BMC Pulm Med; 2010 Feb; 10():7. PubMed ID: 20170555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective.
    Kowada A
    J Infect; 2019 Jan; 78(1):58-65. PubMed ID: 30009853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations.
    Diel R; Lampenius N; Nienhaus A
    Pharmacoeconomics; 2015 Aug; 33(8):783-809. PubMed ID: 25774015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of different screening strategies (single or dual) for the diagnosis of tuberculosis infection in healthcare workers.
    del Campo MT; Fouad H; Solís-Bravo MM; Sánchez-Uriz MA; Mahíllo-Fernández I; Esteban J
    Infect Control Hosp Epidemiol; 2012 Dec; 33(12):1226-34. PubMed ID: 23143360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative study of concordance and costs between tuberculin skin test and QuantiFERON(®)-TB Gold In-Tube in the diagnosis of latent tuberculosis infection among contacts of patients with pulmonary tuberculosis].
    Martinez Lacasa X; Canals Font R; Jaen Manzanera A; Cuchi Burgos E; Lite Lite J
    Med Clin (Barc); 2015 Nov; 145(10):427-32. PubMed ID: 25794770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycobacterium Tuberculosis Infection, Immigration Status, and Diagnostic Discordance: A Comparison of Tuberculin Skin Test and QuantiFERON-TB Gold In-Tube Test Among Immigrants to the U.S.
    Wilson FA; Miller TL; Stimpson JP
    Public Health Rep; 2016; 131(2):303-10. PubMed ID: 26957665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A scoping review of cost-effectiveness of screening and treatment for latent tubercolosis infection in migrants from high-incidence countries.
    Zammarchi L; Casadei G; Strohmeyer M; Bartalesi F; Liendo C; Matteelli A; Bonati M; Gotuzzo E; Bartoloni A;
    BMC Health Serv Res; 2015 Sep; 15():412. PubMed ID: 26399233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of interferon-gamma release assay for systematic tuberculosis screening of healthcare workers in low-incidence countries.
    Kowada A; Takasaki J; Kobayashi N
    J Hosp Infect; 2015 Feb; 89(2):99-108. PubMed ID: 25559158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Priorities for screening and treatment of latent tuberculosis infection in the United States.
    Linas BP; Wong AY; Freedberg KA; Horsburgh CR
    Am J Respir Crit Care Med; 2011 Sep; 184(5):590-601. PubMed ID: 21562129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of cost and cost-effectiveness of different TB-screening strategies.
    Nienhaus A; Schablon A; Costa JT; Diel R
    BMC Health Serv Res; 2011 Sep; 11():247. PubMed ID: 21961888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection.
    Campbell JR; Sasitharan T; Marra F
    Appl Health Econ Health Policy; 2015 Aug; 13(4):325-40. PubMed ID: 26129810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.